NeoOncoRx to start Neotrofin trials

NeoOncoRx, a subsidiary of NeoTherapeutics (NEOT), will begin next quarter two U.S. Phase II trials of Neotrofin in patients with chemotherapy-induced neuropathy. The U.S. trials, which will each enro...